Literature DB >> 31456181

Breast Cancer Heterogeneity in Primary and Metastatic Disease.

Lauren Kalinowski1,2, Jodi M Saunus3, Amy E McCart Reed1, Sunil R Lakhani1,2.   

Abstract

Breast cancer encompasses a heterogeneous collection of neoplasms with diverse morphologies, molecular phenotypes, responses to therapy, probabilities of relapse and overall survival. Traditional histopathological classification aims to categorise tumours into subgroups to inform clinical management decisions, but the diversity within these subgroups remains considerable. Application of massively parallel sequencing technologies in breast cancer research has revealed the true depth of variability in terms of the genetic, phenotypic, cellular and microenvironmental constitution of individual tumours, with the realisation that each tumour is exquisitely unique. This poses great challenges in predicting the development of drug resistance, and treating metastatic disease. Central to achieving fully personalised clinical management is translating new insights on breast cancer heterogeneity into the clinical setting, to evolve the taxonomy of breast cancer and improve risk stratification.

Entities:  

Keywords:  Breast cancer classification; Breast cancer molecular subtypes; Clonal evolution; Heterogeneity; Metastasis; Pathology

Mesh:

Year:  2019        PMID: 31456181     DOI: 10.1007/978-3-030-20301-6_6

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  8 in total

1.  Identification and validation of a novel prognostic signature based on transcription factors in breast cancer by bioinformatics analysis.

Authors:  Yingmei Yang; Zhaoyun Li; Qianyi Zhong; Lei Zhao; Yichao Wang; Hongbo Chi
Journal:  Gland Surg       Date:  2022-05

2.  Mutual exclusivity of ESR1 and TP53 mutations in endocrine resistant metastatic breast cancer.

Authors:  Zheqi Li; Nicole S Spoelstra; Matthew J Sikora; Sharon B Sams; Anthony Elias; Jennifer K Richer; Adrian V Lee; Steffi Oesterreich
Journal:  NPJ Breast Cancer       Date:  2022-05-10

3.  Human Plasma Metabolomics for Biomarker Discovery: Targeting the Molecular Subtypes in Breast Cancer.

Authors:  Leticia Díaz-Beltrán; Carmen González-Olmedo; Natalia Luque-Caro; Caridad Díaz; Ariadna Martín-Blázquez; Mónica Fernández-Navarro; Ana Laura Ortega-Granados; Fernando Gálvez-Montosa; Francisca Vicente; José Pérez Del Palacio; Pedro Sánchez-Rovira
Journal:  Cancers (Basel)       Date:  2021-01-05       Impact factor: 6.639

4.  Drug resistance gene expression and chemotherapy sensitivity detection in Chinese women with different molecular subtypes of breast cancer.

Authors:  Jing Zhao; Hailian Zhang; Ting Lei; Juntian Liu; Shichao Zhang; Nan Wu; Bo Sun; Meng Wang
Journal:  Cancer Biol Med       Date:  2020-12-15       Impact factor: 4.248

5.  Carnitine palmitoyl transferase 1A is a novel diagnostic and predictive biomarker for breast cancer.

Authors:  Zheqiong Tan; Yaru Zou; Man Zhu; Zhenzhao Luo; Tangwei Wu; Chao Zheng; Aqing Xie; Hui Wang; Shiqiang Fang; Shuiyi Liu; Yong Li; Zhongxin Lu
Journal:  BMC Cancer       Date:  2021-04-15       Impact factor: 4.430

6.  Circulating Cell-Free DNA Reflects the Clonal Evolution of Breast Cancer Tumors.

Authors:  Jouni Kujala; Jaana M Hartikainen; Maria Tengström; Reijo Sironen; Päivi Auvinen; Veli-Matti Kosma; Arto Mannermaa
Journal:  Cancers (Basel)       Date:  2022-03-04       Impact factor: 6.639

7.  Repetitive Sequence Transcription in Breast Cancer.

Authors:  Walter Arancio; Claudia Coronnello
Journal:  Cells       Date:  2022-08-14       Impact factor: 7.666

Review 8.  Breast Cancer Chemotherapeutic Options: A General Overview on the Preclinical Validation of a Multi-Target Ruthenium(III) Complex Lodged in Nucleolipid Nanosystems.

Authors:  Maria Grazia Ferraro; Marialuisa Piccolo; Gabriella Misso; Francesco Maione; Daniela Montesarchio; Michele Caraglia; Luigi Paduano; Rita Santamaria; Carlo Irace
Journal:  Cells       Date:  2020-06-05       Impact factor: 6.600

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.